摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-methoxy-8-[(2R)-oxiran-2-ylmethoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine | 1375468-67-9

中文名称
——
中文别名
——
英文名称
7-methoxy-8-[(2R)-oxiran-2-ylmethoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine
英文别名
7-methoxy-8-[[(2R)-oxiran-2-yl]methoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine
7-methoxy-8-[(2R)-oxiran-2-ylmethoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine化学式
CAS
1375468-67-9
化学式
C14H16N4O3
mdl
——
分子量
288.306
InChiKey
QFIVCAYGLLYLBN-MRVPVSSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    530.6±60.0 °C(Predicted)
  • 密度:
    1.60±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.49
  • 重原子数:
    21.0
  • 可旋转键数:
    4.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    84.97
  • 氢给体数:
    1.0
  • 氢受体数:
    7.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES<br/>[FR] 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES À SUBSTITUTION ALCOXY
    申请人:BAYER PHARMA AG
    公开号:WO2012062745A1
    公开(公告)日:2012-05-18
    The present invention relates to alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (I) in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)中R1、R2和R3如权利要求中定义的烷氧基取代的2,3-二氢咪唑[1,2-c]喹唑啉化合物,以及制备所述化合物的方法,用于制备所述化合物的中间体,包含所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗或预防高增殖和/或血管生成障碍的疾病,作为唯一药剂或与其他活性成分结合使用。
  • [EN] ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES<br/>[FR] 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES À SUBSTITUTION ARYLAMINOALCOOL
    申请人:BAYER PHARMA AG
    公开号:WO2012062743A1
    公开(公告)日:2012-05-18
    The present invention relates to substituted phenoxypyridine compounds of general foumula (I); in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and /or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及通式(I)的取代苯氧基吡啶化合物;其中R1、R2和R3如权利要求中所定义,以及制备所述化合物的方法,用于制备所述化合物的中间体,包含所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是用作唯一药剂或与其他活性成分组合使用,治疗或预防过度增殖和/或血管生成紊乱。
  • ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES
    申请人:Scott William Johnston
    公开号:US20130330327A1
    公开(公告)日:2013-12-12
    The present invention relates to alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (I) in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)中R1、R2和R3如权利要求所定义的烷氧基取代的2,3-二氢咪唑[1,2-c]喹唑啉化合物,以制备该化合物的方法,用于制备该化合物的中间体,包含该化合物的药物组合物和制造用于治疗或预防疾病,特别是增殖过度和/或血管生成障碍的药物组合物的制备方法,作为单一药剂或与其他活性成分联合使用的药剂。
  • AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
    申请人:Scott William Johnston
    公开号:US20130317004A1
    公开(公告)日:2013-11-28
    This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    本发明涉及新型2,3-二氢咪唑[1,2-c]喹唑啉化合物,含有这些化合物的药物组合物以及这些化合物或组合物用于磷脂酰肌醇-3-激酶(PI3K)抑制和治疗与磷脂酰肌醇-3-激酶(PI3K)活性相关的疾病,特别是治疗过度增殖和/或血管生成异常的疾病,作为唯一的药物或与其他活性成分联合使用。
  • Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
    申请人:Scott William Johnston
    公开号:US08895549B2
    公开(公告)日:2014-11-25
    This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    本发明涉及新型2,3-二氢咪唑[1,2-c]喹唑啉化合物,含有这种化合物的制药组合物以及使用这些化合物或组合物来抑制磷脂酰肌醇-3-激酶(PI3K)并治疗与磷脂酰肌醇-3-激酶(PI3K)活性相关的疾病,特别是治疗过度增殖和/或血管生成障碍,作为唯一的药物或与其他活性成分联合使用。
查看更多